Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy Alone Vs Three Dimensional Conformal Therapy / Intensity Modulated Radiotherapy Plus Adjuvant Hormonal Therapy In Localized T1b-c, T2a, N0, M0 Prostatic Carcinoma. A Phase III Randomized Study
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
This PHASE3 trial investigates Prostate Cancer and is currently completed. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arnhem, Netherlands, Barcelona, Spain, Belfast, United Kingdom, Besançon, France, Brescia, Italy, Brussels, Belgium, Dijon, France, Dublin, Ireland, Esch-sur-Alzette, Luxembourg, Gdansk, Poland and 9 more location s